Current Protein Identity:P11362 New Search
Main Difference Dimensions in This Set
Different construct Different mutation/modification Different assembly state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics

Difference tags compare only the current result set; every original PDB and assembly record remains separate.

Related-Structure Differences

Each row represents one biological assembly in one PDB entry; multiple monomers of the same protein are listed separately.

PDB Entry Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Experimental Method Experimental Conditions Structure Quality
1AGW CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR Deposited 1997-03-25 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 456–765(310 aa) Fragment:TYROSINE KINASE DOMAIN
Mutation:L457V, C488A, C584S SU2 3-[4-(1-FORMYLPIPERAZIN-4-YL)-BENZYLIDENYL]-2-INDOLINONE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;16% PEG 10000, 0.3 M (NH4)2SO4, 100 MM BIS-TRIS, PH 6.5, 5% ETHYLENE GLYCOL
Resolution 2.40 Å R-free 0.280
1AGW CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR Deposited 1997-03-25 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 456–765(310 aa) Fragment:TYROSINE KINASE DOMAIN
Mutation:L457V, C488A, C584S SU2 3-[4-(1-FORMYLPIPERAZIN-4-YL)-BENZYLIDENYL]-2-INDOLINONE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;16% PEG 10000, 0.3 M (NH4)2SO4, 100 MM BIS-TRIS, PH 6.5, 5% ETHYLENE GLYCOL
Resolution 2.40 Å R-free 0.280
1CVS CRYSTAL STRUCTURE OF A DIMERIC FGF2-FGFR1 COMPLEX Deposited 1999-08-24 Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric(4) Consistent with protein count
Chain C 141–365(225 aa) Fragment:IG-LIKE DOMAINS 2 AND 3
Chain D 141–365(225 aa) Fragment:IG-LIKE DOMAINS 2 AND 3
Mutation:YES Mutation:YES SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;298 K;ammonium sulfate, glycerol, Tris-HCl, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.80 Å R-free 0.281
1CVS CRYSTAL STRUCTURE OF A DIMERIC FGF2-FGFR1 COMPLEX Deposited 1999-08-24 Assembly 2 Protein heterocomplex Heteromer;Protein × 8 PDB declaration: octameric(8) Consistent with protein count
Chain C 141–365(225 aa) Fragment:IG-LIKE DOMAINS 2 AND 3
Chain D 141–365(225 aa) Fragment:IG-LIKE DOMAINS 2 AND 3
Mutation:YES Mutation:YES SO4 SULFATE ION × 8 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;298 K;ammonium sulfate, glycerol, Tris-HCl, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.80 Å R-free 0.281
1EVT CRYSTAL STRUCTURE OF FGF1 IN COMPLEX WITH THE EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 1 (FGFR1) Deposited 2000-04-20 Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric(4) Consistent with protein count
Chain C 141–365(225 aa) Fragment:EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 1 (FGFR1) CONSISTING OF IMMUNOGLOBULIN LIKE DOMAINS II (D2) AND III (D3)
Chain D 141–365(225 aa) Fragment:EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 1 (FGFR1) CONSISTING OF IMMUNOGLOBULIN LIKE DOMAINS II (D2) AND III (D3)
Not recorded SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;pH 7.5;298 K;PEG 4000, Isopropanol, HEPES-NaOH, pH 7.5, VAPOR DIFFUSION, temperature 298.0K
Resolution 2.80 Å R-free 0.300
1FGI CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR Deposited 1997-03-22 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 456–765(310 aa) Fragment:TYROSINE KINASE DOMAIN
Mutation:L457V, C488A, C584S SU1 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;16% PEG 10000, 0.3 M (NH4)2SO4, 100 MM BIS-TRIS, PH 6.5, 5% ETHYLENE GLYCOL
Resolution 2.50 Å R-free 0.270
1FGI CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR Deposited 1997-03-22 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 456–765(310 aa) Fragment:TYROSINE KINASE DOMAIN
Mutation:L457V, C488A, C584S SU1 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;16% PEG 10000, 0.3 M (NH4)2SO4, 100 MM BIS-TRIS, PH 6.5, 5% ETHYLENE GLYCOL
Resolution 2.50 Å R-free 0.270
1FGK CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 Deposited 1997-02-08 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 456–765(310 aa) Fragment:TYROSINE KINASE DOMAIN, HUMAN FGFR1 RESIDUES THAT POSSESS PTK ACTIVITY
Chain B 456–765(310 aa) Fragment:TYROSINE KINASE DOMAIN, HUMAN FGFR1 RESIDUES THAT POSSESS PTK ACTIVITY
Mutation:L457V, C488A, C584S Mutation:L457V, C488A, C584S No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;16% PEG 10000, 0.3 M (NH4)2SO4, 100 MM BIS-TRIS, PH 6.5
Resolution 2.00 Å R-free 0.261
1FQ9 CRYSTAL STRUCTURE OF A TERNARY FGF2-FGFR1-HEPARIN COMPLEX Deposited 2000-09-04 Assembly 1 Other combination Heteromer;Protein × 4 PDB declaration: tetrameric(4) Consistent with protein count
Chain C 141–365(225 aa) Fragment:EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 1 (FGFR1) CONSISTING OF IMMUNOGLOBULIN LIKE DOMAINS II (D2) AND III (D3)
Chain D 141–365(225 aa) Fragment:EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 1 (FGFR1) CONSISTING OF IMMUNOGLOBULIN LIKE DOMAINS II (D2) AND III (D3)
Mutation:N185Q Mutation:N185Q No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;298 K;Ammonium sulfate, Glycerol, Tris-HCl, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
Resolution 3.00 Å R-free 0.282
1XR0 Structural Basis of SNT PTB Domain Interactions with Distinct Neurotrophic Receptors Deposited 2004-10-13 Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 409–430(22 aa) Fragment:Sequence database residues 409-430 from the juxtamembrane region of hFGFR1
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 6.5;303 K;Ionic strength (raw mmCIF value) 15 mM DTT-d10, and 0.5 mM EDTA00 mM phosphate buffer,;Pressure 1
NMR sample composition SNT-1 PTB domain/hFGFR1 peptide complex (1:1) of ~0.5 mM in 100 mM phosphate buffer of pH 6.5, 5 mM DTT-d10, and 0.5 mM EDTA in H2O/2H2O (9/1) or 2H2O | H2O/2H2O (9/1) or 100% 2H2O
Resolution not provided
2CR3 Solution structure of the first Ig-like domain of human fibroblast growth factor receptor 1 Deposited 2005-05-20 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 38–123(86 aa) Fragment:Ig domain
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7;298 K;Ionic strength (raw mmCIF value) 120mM;Pressure ambient
NMR sample composition 1.22mM 13C, 15N-labeled protein; 20mM d-Tris-HCl (pH7.0); 100mM NaCl; 1mM DTT; 0.02% NaN3 | 90% H2O/10% D2O
Resolution not provided
2FGI CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074 Deposited 1998-09-15 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 456–765(310 aa) Fragment:TYROSINE KINASE DOMAIN
Chain B 456–765(310 aa) Fragment:TYROSINE KINASE DOMAIN
Mutation:L457V, C488A, C584S Mutation:L457V, C488A, C584S PD1 1-TERT-BUTYL-3-[6-(3,5-DIMETHOXY-PHENYL)-2-(4-DIETHYLAMINO-BUTYLAMINO)-PYRIDO[2,3-D]PYRIMIDIN-7-YL]-UREA × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;16% PEG 10000, 0.3 M (NH4)2SO4, 100 MM BIS-TRIS, PH 6.5, 5% ETHYLENE GLYCOL
Resolution 2.50 Å R-free 0.264
3C4F FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3-methoxybenzyl)-7-azaindole Deposited 2008-01-29 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 464–765(302 aa) Fragment:KINASE DOMAIN
Mutation:C488A C4F 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;277 K;16% PEG10k, 0.3M (NH4)2SO4, 5% Ethylene Glycol, 100 mM Bis-Tris pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 2.07 Å R-free 0.264
3C4F FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3-methoxybenzyl)-7-azaindole Deposited 2008-01-29 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 464–765(302 aa) Fragment:KINASE DOMAIN
Mutation:C488A C4F 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;277 K;16% PEG10k, 0.3M (NH4)2SO4, 5% Ethylene Glycol, 100 mM Bis-Tris pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 2.07 Å R-free 0.264
3C4F FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3-methoxybenzyl)-7-azaindole Deposited 2008-01-29 Assembly 3 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 464–765(302 aa) Fragment:KINASE DOMAIN
Mutation:C488A C4F 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;277 K;16% PEG10k, 0.3M (NH4)2SO4, 5% Ethylene Glycol, 100 mM Bis-Tris pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 2.07 Å R-free 0.264
3DPK cFMS tyrosine kinase in complex with a pyridopyrimidinone inhibitor Deposited 2008-07-08 Assembly 1 Insufficient information Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 577–597(21 aa) Fragment:KINASE DOMAIN
Mutation:Native kinase insert domain replaced by FGF receptor kinase insert domain SO4 SULFATE ION × 3 8C5 8-cyclohexyl-N-methoxy-5-oxo-2-{[4-(2-pyrrolidin-1-ylethyl)phenyl]amino}-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 5.2;298 K;PEG 3350, SODIUM ACETATE, LI2SO4, pH 5.2, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.95 Å R-free 0.244
3GQI Crystal Structure of activated receptor tyrosine kinase in complex with substrates Deposited 2009-03-24 Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–774(317 aa) Fragment:Protein kinase domain
Mutation:C488A, Y583F, C584S, Y575F Non-standard monomer:Yes (specific site not provided by mmCIF) DVT DECAVANADATE × 1 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8;277 K;PEg 8000, taurine, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.50 Å R-free 0.289
3GQL Crystal Structure of activated receptor tyrosine kinase in complex with substrates Deposited 2009-03-24 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–774(317 aa) Fragment:protein kinase domain
Mutation:C488A GQL (E)-[4-(3,5-difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;277 K;PEG 8000, (NH4)2SO4, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.80 Å R-free 0.289
3GQL Crystal Structure of activated receptor tyrosine kinase in complex with substrates Deposited 2009-03-24 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–774(317 aa) Fragment:protein kinase domain
Mutation:C488A GQL (E)-[4-(3,5-difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;277 K;PEG 8000, (NH4)2SO4, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.80 Å R-free 0.289
3GQL Crystal Structure of activated receptor tyrosine kinase in complex with substrates Deposited 2009-03-24 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 458–774(317 aa) Fragment:protein kinase domain
Mutation:C488A GQL (E)-[4-(3,5-difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;277 K;PEG 8000, (NH4)2SO4, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.80 Å R-free 0.289
3GQL Crystal Structure of activated receptor tyrosine kinase in complex with substrates Deposited 2009-03-24 Assembly 4 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–774(317 aa) Fragment:protein kinase domain
Chain B 458–774(317 aa) Fragment:protein kinase domain
Mutation:C488A Mutation:C488A GQL (E)-[4-(3,5-difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5;277 K;PEG 8000, (NH4)2SO4, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.80 Å R-free 0.289
3JS2 Crystal structure of minimal kinase domain of fibroblast growth factor receptor 1 in complex with 5-(2-thienyl)nicotinic acid Deposited 2009-09-09 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–765(308 aa) Fragment:Kinase domain: UNP residues 459-765
Chain B 458–765(308 aa) Fragment:Kinase domain: UNP residues 459-765
Mutation:C488A, C584S Mutation:C488A, C584S VM1 5-(2-thienyl)nicotinic acid × 2 PO4 PHOSPHATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;0.2M Ammonium sulfate, 0.1M MES pH 6.5, 15% PEG 4000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.20 Å R-free 0.259
3JS2 Crystal structure of minimal kinase domain of fibroblast growth factor receptor 1 in complex with 5-(2-thienyl)nicotinic acid Deposited 2009-09-09 Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–765(308 aa) Fragment:Kinase domain: UNP residues 459-765
Chain B 458–765(308 aa) Fragment:Kinase domain: UNP residues 459-765
Mutation:C488A, C584S Mutation:C488A, C584S VM1 5-(2-thienyl)nicotinic acid × 2 PO4 PHOSPHATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;0.2M Ammonium sulfate, 0.1M MES pH 6.5, 15% PEG 4000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.20 Å R-free 0.259
3KRJ cFMS tyrosine kinase in complex with 4-Cyano-1H-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide Deposited 2009-11-18 Assembly 1 Insufficient information Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 577–597(21 aa) Fragment:UNP residues 538-678, 753-922
Mutation:C584S ACT ACETATE ION × 1 KRJ 4-cyano-N-(2-cyclohex-1-en-1-yl-4-piperidin-4-ylphenyl)-1H-imidazole-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 5.6;293 K;13-19%PRG3350 100mM NaAcetate, pH 5.6 200mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.10 Å R-free 0.260
3KRL cFMS Tyrosine kinase in complex with 5-Cyano-furan-2-carboxylic acid [4-(4-methyl-piperazin-1-yl)-2-piperidin-1-yl-phenyl]-amide Deposited 2009-11-18 Assembly 1 Insufficient information Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 577–597(21 aa) Fragment:UNP residues 538-678, 753-922
Mutation:C584S KRL 5-cyano-N-[4-(4-methylpiperazin-1-yl)-2-piperidin-1-ylphenyl]furan-2-carboxamide × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 5.6;295 K;13-19% PEG3350 100mM NaAc pH 5.6 200mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.40 Å R-free 0.264
3KXX Structure of the mutant Fibroblast Growth Factor receptor 1 Deposited 2009-12-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa) Fragment:Kinase domain (UNP residues 458 to 765)
Mutation:C488A, R577E, C584S No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8;298 K;Crystals were grown at room temperature in 14 days using the hanging drop technique containing equal volumes of protein solution and reservoir buffer (15 % [w/v] polyethylene glycol 3350, 200 mM lithium citrate). , pH 8, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 3.20 Å R-free 0.263
3KXX Structure of the mutant Fibroblast Growth Factor receptor 1 Deposited 2009-12-04 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa) Fragment:Kinase domain (UNP residues 458 to 765)
Mutation:C488A, R577E, C584S No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8;298 K;Crystals were grown at room temperature in 14 days using the hanging drop technique containing equal volumes of protein solution and reservoir buffer (15 % [w/v] polyethylene glycol 3350, 200 mM lithium citrate). , pH 8, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 3.20 Å R-free 0.263
3KXX Structure of the mutant Fibroblast Growth Factor receptor 1 Deposited 2009-12-04 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 458–765(308 aa) Fragment:Kinase domain (UNP residues 458 to 765)
Mutation:C488A, R577E, C584S No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8;298 K;Crystals were grown at room temperature in 14 days using the hanging drop technique containing equal volumes of protein solution and reservoir buffer (15 % [w/v] polyethylene glycol 3350, 200 mM lithium citrate). , pH 8, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 3.20 Å R-free 0.263
3KXX Structure of the mutant Fibroblast Growth Factor receptor 1 Deposited 2009-12-04 Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain D 458–765(308 aa) Fragment:Kinase domain (UNP residues 458 to 765)
Mutation:C488A, R577E, C584S No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8;298 K;Crystals were grown at room temperature in 14 days using the hanging drop technique containing equal volumes of protein solution and reservoir buffer (15 % [w/v] polyethylene glycol 3350, 200 mM lithium citrate). , pH 8, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 3.20 Å R-free 0.263
3KXX Structure of the mutant Fibroblast Growth Factor receptor 1 Deposited 2009-12-04 Assembly 5 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–765(308 aa) Fragment:Kinase domain (UNP residues 458 to 765)
Chain D 458–765(308 aa) Fragment:Kinase domain (UNP residues 458 to 765)
Mutation:C488A, R577E, C584S Mutation:C488A, R577E, C584S No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8;298 K;Crystals were grown at room temperature in 14 days using the hanging drop technique containing equal volumes of protein solution and reservoir buffer (15 % [w/v] polyethylene glycol 3350, 200 mM lithium citrate). , pH 8, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 3.20 Å R-free 0.263
3KXX Structure of the mutant Fibroblast Growth Factor receptor 1 Deposited 2009-12-04 Assembly 6 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain B 458–765(308 aa) Fragment:Kinase domain (UNP residues 458 to 765)
Chain C 458–765(308 aa) Fragment:Kinase domain (UNP residues 458 to 765)
Mutation:C488A, R577E, C584S Mutation:C488A, R577E, C584S No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8;298 K;Crystals were grown at room temperature in 14 days using the hanging drop technique containing equal volumes of protein solution and reservoir buffer (15 % [w/v] polyethylene glycol 3350, 200 mM lithium citrate). , pH 8, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 3.20 Å R-free 0.263
3KY2 Crystal structure of Fibroblast Growth Factor Receptor 1 kinase domain Deposited 2009-12-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa) Fragment:Kinase domain (UNP residues 458 to 765)
Mutation:C488A, C584S SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;0.4 M (NH4)2SO4, 15 % PEG 4000, 5 % Glycerol for 1 week., pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.70 Å R-free 0.252
3KY2 Crystal structure of Fibroblast Growth Factor Receptor 1 kinase domain Deposited 2009-12-04 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa) Fragment:Kinase domain (UNP residues 458 to 765)
Mutation:C488A, C584S SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;0.4 M (NH4)2SO4, 15 % PEG 4000, 5 % Glycerol for 1 week., pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.70 Å R-free 0.252
3OJV Crystal Structure of FGF1 complexed with the ectodomain of FGFR1c exhibiting an ordered ligand specificity-determining betaC'-betaE loop Deposited 2010-08-23 Assembly 1 Other combination Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain C 142–365(224 aa) Fragment:FGFR1c
Mutation:N185Q No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;293 K;0.1M Tris, 15% PEG4000, 0.1M ammonium sulfate, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.60 Å R-free 0.309
3OJV Crystal Structure of FGF1 complexed with the ectodomain of FGFR1c exhibiting an ordered ligand specificity-determining betaC'-betaE loop Deposited 2010-08-23 Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain D 142–365(224 aa) Fragment:FGFR1c
Mutation:N185Q No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;293 K;0.1M Tris, 15% PEG4000, 0.1M ammonium sulfate, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.60 Å R-free 0.309
3RHX Crystal structure of the catalytic domain of FGFR1 kinase in complex with ARQ 069 Deposited 2011-04-12 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 461–765(305 aa) Fragment:UNP residues 461-765
Mutation:C488A, C584S 3RH (6S)-6-phenyl-5,6-dihydrobenzo[h]quinazolin-2-amine × 1 SO4 SULFATE ION × 1 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;PEG 10000, 0.3M (NH4)2SO4, 5% ethylene glycol, 100mM MES, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.01 Å R-free 0.262
3RHX Crystal structure of the catalytic domain of FGFR1 kinase in complex with ARQ 069 Deposited 2011-04-12 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 461–765(305 aa) Fragment:UNP residues 461-765
Mutation:C488A, C584S 3RH (6S)-6-phenyl-5,6-dihydrobenzo[h]quinazolin-2-amine × 1 EDO 1,2-ETHANEDIOL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;PEG 10000, 0.3M (NH4)2SO4, 5% ethylene glycol, 100mM MES, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.01 Å R-free 0.262
3TT0 Co-structure of Fibroblast Growth Factor Receptor 1 kinase domain with 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (BGJ398) Deposited 2011-09-13 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 456–765(310 aa) Fragment:kinase domain, UNP residues 456-769
Mutation:C584S 07J 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)-1-methylurea × 1 SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;277 K;CRYSTALLIZED FROM RESERVOIR CONTAINING 18-28% (V:V) PEG-MME 5000, 0.2 M AMSO4, AND 0.1 M SODIUM CACODYLATE , pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.80 Å R-free 0.261
3TT0 Co-structure of Fibroblast Growth Factor Receptor 1 kinase domain with 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (BGJ398) Deposited 2011-09-13 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 456–765(310 aa) Fragment:kinase domain, UNP residues 456-769
Mutation:C584S 07J 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)-1-methylurea × 1 SO4 SULFATE ION × 1 GOL GLYCEROL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;277 K;CRYSTALLIZED FROM RESERVOIR CONTAINING 18-28% (V:V) PEG-MME 5000, 0.2 M AMSO4, AND 0.1 M SODIUM CACODYLATE , pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.80 Å R-free 0.261
4F63 Crystal structure of Human Fibroblast Growth Factor Receptor 1 Kinase domain in complex with compound 1 Deposited 2012-05-14 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–765(308 aa) Fragment:kinase domain (UNP residues 458-765)
Chain B 458–765(308 aa) Fragment:kinase domain (UNP residues 458-765)
Mutation:C488A, C584S Mutation:C488A, C584S 0S7 5-bromo-N~4~-(3-methyl-1H-pyrazol-5-yl)-N~2~-[2-(pyridin-3-yl)ethyl]pyrimidine-2,4-diamine × 2 EDO 1,2-ETHANEDIOL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;16-20% PEG8000, 100 mM PCTP, 100-300 mM ammonium sulfate, 25% ethylene glycol, pH 6.25-7.25, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.55 Å R-free 0.287
4F64 Crystal structure of Human Fibroblast Growth Factor Receptor 1 Kinase domain in complex with compound 6 Deposited 2012-05-14 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–765(308 aa) Fragment:kinase domain (UNP residues 458-765)
Chain B 458–765(308 aa) Fragment:kinase domain (UNP residues 458-765)
Mutation:C488A, C584S Mutation:C488A, C584S 0S8 5-bromo-N~4~-[3-(3-methoxypropyl)-1H-pyrazol-5-yl]-N~2~-[(3-methyl-1,2-oxazol-5-yl)methyl]pyrimidine-2,4-diamine × 2 EDO 1,2-ETHANEDIOL × 4 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;16-20% PEG8000, 100 mM PCTP, 100-300 mM ammonium sulfate, 25% ethylene glycol, pH 6.25-7.25, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.05 Å R-free 0.269
4F65 Crystal structure of Human Fibroblast Growth Factor Receptor 1 Kinase domain in complex with compound 8 Deposited 2012-05-14 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–765(308 aa) Fragment:kinase domain (UNP residues 458-765)
Chain B 458–765(308 aa) Fragment:kinase domain (UNP residues 458-765)
Mutation:C488A, C584S Mutation:C488A, C584S SO4 SULFATE ION × 4 EDO 1,2-ETHANEDIOL × 10 0S9 5-bromo-N~2~-[(3-methyl-1,2-oxazol-5-yl)methyl]-N~4~-[3-(2-phenylethyl)-1H-pyrazol-5-yl]pyrimidine-2,4-diamine × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;16-20% PEG8000, 100 mM PCTP, 100-300 mM ammonium sulfate, 25% ethylene glycol, pH 6.25-7.25, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.26 Å R-free 0.235
4NK9 Crystal structure of human fibroblast growth factor receptor 1 kinase domain in complex with pyrazolaminopyrimidine 1 Deposited 2013-11-12 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–765(308 aa) Fragment:KINASE DOMAIN (UNP RESIDUES 458-765)
Chain B 458–765(308 aa) Fragment:KINASE DOMAIN (UNP RESIDUES 458-765)
Mutation:YES Mutation:YES EDO 1,2-ETHANEDIOL × 4 SO4 SULFATE ION × 3 2K5 N~4~-{5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl}-N~2~-[(3-methyl-1,2-oxazol-5-yl)methyl]pyrimidine-2,4-diamine × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.75;277.15 K;18-20% PEG 8000, 100mM PCTP, 200mM ammonium sulfate, 25% ethylene glycol, pH 6.75, VAPOR DIFFUSION, HANGING DROP, temperature 277.15K
Resolution 2.57 Å R-free 0.262
4NKA Crystal structure of human fibroblast growth factor receptor 1 kinase domain in complex with pyrazolaminopyrimidine 2 Deposited 2013-11-12 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 458–765(308 aa) Fragment:KINASE DOMAIN (UNP RESIDUES 458-765)
Chain B 458–765(308 aa) Fragment:KINASE DOMAIN (UNP RESIDUES 458-765)
Mutation:C488A, C584S Mutation:C488A, C584S SO4 SULFATE ION × 3 EDO 1,2-ETHANEDIOL × 3 2K7 N~4~-{3-[2-(3,4-dimethoxyphenyl)ethyl]-1H-pyrazol-5-yl}-N~2~-[(3-methyl-1,2-oxazol-5-yl)methyl]pyrimidine-2,4-diamine × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.75;277.15 K;18-20% PEG 8000, 100mM PCTP, 200mM ammonium sulfate, 25% ethylene glycol, pH 6.75, VAPOR DIFFUSION, HANGING DROP, temperature 277.15K
Resolution 2.19 Å R-free 0.228
4NKS Crystal structure of human fibroblast growth factor receptor 1 kinase domain in complex with pyrazolaminopyrimidine 3 Deposited 2013-11-13 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa) Fragment:KINASE DOMAIN (UNP RESIDUES 458-765)
Mutation:C488A, C584S 2M2 N~2~-[(3-methyl-1,2-oxazol-5-yl)methyl]-N~4~-[5-(2-phenylethyl)-1H-pyrazol-3-yl]pyrimidine-2,4-diamine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.75;277.15 K;16-20% PEG 8000, 100mM PCTP, 100-300mM ammonium sulfate, 25% ethylene glycol, pH 6.75, VAPOR DIFFUSION, HANGING DROP, temperature 277.15K
Resolution 2.50 Å R-free 0.278
4NKS Crystal structure of human fibroblast growth factor receptor 1 kinase domain in complex with pyrazolaminopyrimidine 3 Deposited 2013-11-13 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa) Fragment:KINASE DOMAIN (UNP RESIDUES 458-765)
Mutation:C488A, C584S 2M2 N~2~-[(3-methyl-1,2-oxazol-5-yl)methyl]-N~4~-[5-(2-phenylethyl)-1H-pyrazol-3-yl]pyrimidine-2,4-diamine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.75;277.15 K;16-20% PEG 8000, 100mM PCTP, 100-300mM ammonium sulfate, 25% ethylene glycol, pH 6.75, VAPOR DIFFUSION, HANGING DROP, temperature 277.15K
Resolution 2.50 Å R-free 0.278
4RWI Crystal structure of V561M FGFR1 gatekeeper mutation (C488A, C584S, V561M), apo Deposited 2014-12-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa) Fragment:Residues 458-765
Mutation:C488A, C584S, V561M No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.4;293 K;0.1 M sodium cacodylate pH 6.4, 30% PEG 8000, 0.2 M ammonium sulfate, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.29 Å R-free 0.236
4RWI Crystal structure of V561M FGFR1 gatekeeper mutation (C488A, C584S, V561M), apo Deposited 2014-12-04 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa) Fragment:Residues 458-765
Mutation:C488A, C584S, V561M No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.4;293 K;0.1 M sodium cacodylate pH 6.4, 30% PEG 8000, 0.2 M ammonium sulfate, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.29 Å R-free 0.236
4RWJ Crystal Structure of FGFR1 (C488A, C584S) in complex with AZD4547 (N-{3-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) Deposited 2014-12-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa) Fragment:Residues 458-765
Mutation:C488A, C584S 66T N-{3-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-5-yl}-4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.4;277 K;0.1 M sodium cacodylate pH 6.4, 22% PEG 8000, 0.2 M ammonium sulfate, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.49 Å R-free 0.250
4RWJ Crystal Structure of FGFR1 (C488A, C584S) in complex with AZD4547 (N-{3-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) Deposited 2014-12-04 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa) Fragment:Residues 458-765
Mutation:C488A, C584S 66T N-{3-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-5-yl}-4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.4;277 K;0.1 M sodium cacodylate pH 6.4, 22% PEG 8000, 0.2 M ammonium sulfate, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.49 Å R-free 0.250
4RWK Crystal structure of V561M FGFR1 gatekeeper mutation (C488A, C584S, V561M) in complex with N-{3-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547) Deposited 2014-12-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa) Fragment:Residues 458-765
Mutation:C488A, C584S, V561M 66T N-{3-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-5-yl}-4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]benzamide × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.6;293 K;0.1 M MES pH 6.6, 34% PEG 8000, 0.2 M ammonium sulfate, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.98 Å R-free 0.299
4RWK Crystal structure of V561M FGFR1 gatekeeper mutation (C488A, C584S, V561M) in complex with N-{3-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547) Deposited 2014-12-04 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa) Fragment:Residues 458-765
Mutation:C488A, C584S, V561M 66T N-{3-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-5-yl}-4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.6;293 K;0.1 M MES pH 6.6, 34% PEG 8000, 0.2 M ammonium sulfate, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.98 Å R-free 0.299
4RWL Crystal structure of FGFR1 (C488A, C584C) in complex with 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide (E3810) Deposited 2014-12-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa) Fragment:Residues 458-765
Mutation:C488A, C584S No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.6;293 K;0.1 M sodium cacodylate pH 6.6, 34% PEG 8000, 0.2 M ammonium sulfate, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.19 Å R-free 0.256
4RWL Crystal structure of FGFR1 (C488A, C584C) in complex with 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide (E3810) Deposited 2014-12-04 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa) Fragment:Residues 458-765
Mutation:C488A, C584S 3ZC 6-({7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-N-methylnaphthalene-1-carboxamide × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.6;293 K;0.1 M sodium cacodylate pH 6.6, 34% PEG 8000, 0.2 M ammonium sulfate, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.19 Å R-free 0.256
4UWB Fibroblast growth factor receptor 1 kinase in complex with JK-P5 Deposited 2014-08-11 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa) Fragment:KINASE DOMAIN, RESIDUES 458-765
Mutation:YES EDO 1,2-ETHANEDIOL × 3 JVT N-[4-(4-methylpiperazin-1-yl)phenyl]-1H-indazole-3-carboxamide × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 20% PEG8000, 20% ETHLYENE GLYCOL, 0.2M AMMONIUM SULPHATE, 0.1M PCTP PH 6.75
Resolution 2.31 Å R-free 0.272
4UWB Fibroblast growth factor receptor 1 kinase in complex with JK-P5 Deposited 2014-08-11 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa) Fragment:KINASE DOMAIN, RESIDUES 458-765
Mutation:YES EDO 1,2-ETHANEDIOL × 2 JVT N-[4-(4-methylpiperazin-1-yl)phenyl]-1H-indazole-3-carboxamide × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 20% PEG8000, 20% ETHLYENE GLYCOL, 0.2M AMMONIUM SULPHATE, 0.1M PCTP PH 6.75
Resolution 2.31 Å R-free 0.272
4UWC Fibroblast growth factor receptor 1 kinase in complex with JK-P3 Deposited 2014-08-11 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa) Fragment:KINASE DOMAIN, RESIDUES 458-765
Mutation:YES EDO 1,2-ETHANEDIOL × 7 4Y0 3,4-dimethoxy-N-(5-phenyl-1H-pyrazol-3-yl)benzamide × 1 PPI PROPANOIC ACID × 2 SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions 20% PEG8000, 20% ETHYLENE GLYCOL, 0.2M AMMONIUM SULPHATE, 0.1M PCTP PH 6.75
Resolution 1.96 Å R-free 0.206
4UWC Fibroblast growth factor receptor 1 kinase in complex with JK-P3 Deposited 2014-08-11 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa) Fragment:KINASE DOMAIN, RESIDUES 458-765
Mutation:YES EDO 1,2-ETHANEDIOL × 5 4Y0 3,4-dimethoxy-N-(5-phenyl-1H-pyrazol-3-yl)benzamide × 1 PPI PROPANOIC ACID × 1 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions 20% PEG8000, 20% ETHYLENE GLYCOL, 0.2M AMMONIUM SULPHATE, 0.1M PCTP PH 6.75
Resolution 1.96 Å R-free 0.206
4UWY FGFR1 Apo structure Deposited 2014-08-15 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa) Fragment:KINASE DOMAIN, RESIDUES 458-765
Not recorded PEG DI(HYDROXYETHYL)ETHER × 1 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5;20 % PEG 5K MME, 0.1 M TRIS, PH 7.5, 0.2 M (NH4)2SO4
Resolution 2.31 Å R-free 0.267
4UWY FGFR1 Apo structure Deposited 2014-08-15 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa) Fragment:KINASE DOMAIN, RESIDUES 458-765
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5;20 % PEG 5K MME, 0.1 M TRIS, PH 7.5, 0.2 M (NH4)2SO4
Resolution 2.31 Å R-free 0.267
4WUN Structure of FGFR1 in complex with AZD4547 (N-{3-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) at 1.65 angstrom Deposited 2014-11-02 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 490–796(307 aa) Fragment:UNP residues 311-490
Not recorded 66T N-{3-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-5-yl}-4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;291 K;20% MPEG 5000, 0.1 M sodium cacodylate pH 7.5, 0.2 M ammonium sulfate
Resolution 1.65 Å R-free 0.247
4WUN Structure of FGFR1 in complex with AZD4547 (N-{3-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) at 1.65 angstrom Deposited 2014-11-02 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 490–796(307 aa) Fragment:UNP residues 311-490
Not recorded 66T N-{3-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-5-yl}-4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;291 K;20% MPEG 5000, 0.1 M sodium cacodylate pH 7.5, 0.2 M ammonium sulfate
Resolution 1.65 Å R-free 0.247
4ZSA Crystal structure of FGFR1 kinase domain in complex with 7n Deposited 2015-05-13 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa) Fragment:UNP residues 458-765
Mutation:C488A, C584S 4UT 4-(4-ethylpiperazin-1-yl)-N-[6-(3-methoxyphenyl)-2H-indazol-3-yl]benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;0.1M Bis-Tris pH 6.5, 0.3M (NH4)2SO4, 15-20% PEG10000, 5% EG
Resolution 2.00 Å R-free 0.254
4ZSA Crystal structure of FGFR1 kinase domain in complex with 7n Deposited 2015-05-13 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa) Fragment:UNP residues 458-765
Mutation:C488A, C584S 4UT 4-(4-ethylpiperazin-1-yl)-N-[6-(3-methoxyphenyl)-2H-indazol-3-yl]benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;0.1M Bis-Tris pH 6.5, 0.3M (NH4)2SO4, 15-20% PEG10000, 5% EG
Resolution 2.00 Å R-free 0.254
5A4C FGFR1 ligand complex Deposited 2015-06-05 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 461–765(305 aa) Fragment:RESIDUES 461-765
Mutation:YES SO4 SULFATE ION × 5 EDO 1,2-ETHANEDIOL × 5 XOJ 1-tert-butyl-3-[2-[3-(diethylamino)propylamino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]urea × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.09 Å R-free 0.235
5A4C FGFR1 ligand complex Deposited 2015-06-05 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 461–765(305 aa) Fragment:RESIDUES 461-765
Mutation:YES SO4 SULFATE ION × 1 EDO 1,2-ETHANEDIOL × 5 XOJ 1-tert-butyl-3-[2-[3-(diethylamino)propylamino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]urea × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.09 Å R-free 0.235
5AM6 Native FGFR1 with an inhibitor Deposited 2015-03-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa) Fragment:KINASE DOMAIN, RESIDUES 458-765
Not recorded CL CHLORIDE ION × 3 38O 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8;20 % PEG 5K MME, 0.1 M TRIS, PH 7.5, 0.2 M (NH4)2SO4
Resolution 1.96 Å R-free 0.252
5AM6 Native FGFR1 with an inhibitor Deposited 2015-03-10 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa) Fragment:KINASE DOMAIN, RESIDUES 458-765
Not recorded 38O 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8;20 % PEG 5K MME, 0.1 M TRIS, PH 7.5, 0.2 M (NH4)2SO4
Resolution 1.96 Å R-free 0.252
5AM7 FGFR1 mutant with an inhibitor Deposited 2015-03-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa) Fragment:KINASE DOMAIN, UNP RESIDUES 458-765
Mutation:YES 38O 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one × 1 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8;20 % PEG 5K MME, 0.1 M TRIS, PH 7.5, 0.2 M (NH4)2SO4
Resolution 1.96 Å R-free 0.254
5AM7 FGFR1 mutant with an inhibitor Deposited 2015-03-10 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa) Fragment:KINASE DOMAIN, UNP RESIDUES 458-765
Mutation:YES 38O 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8;20 % PEG 5K MME, 0.1 M TRIS, PH 7.5, 0.2 M (NH4)2SO4
Resolution 1.96 Å R-free 0.254
5B7V Human FGFR1 kinase in complex with CH5183284 Deposited 2016-06-09 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 456–765(310 aa) Fragment:tyrosine kinase domain, UNP residues 456-765
Mutation:L457V, C488A, C584S LWJ [5-amino-1-(2-methyl-1H-benzimidazol-6-yl)-1H-pyrazol-4-yl](1H-indol-2-yl)methanone × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;PEG 10000, (NH4)2SO4, BIS-TRIS
Resolution 2.15 Å R-free 0.256
5B7V Human FGFR1 kinase in complex with CH5183284 Deposited 2016-06-09 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 456–765(310 aa) Fragment:tyrosine kinase domain, UNP residues 456-765
Mutation:L457V, C488A, C584S LWJ [5-amino-1-(2-methyl-1H-benzimidazol-6-yl)-1H-pyrazol-4-yl](1H-indol-2-yl)methanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;PEG 10000, (NH4)2SO4, BIS-TRIS
Resolution 2.15 Å R-free 0.256
5EW8 FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693 Deposited 2015-11-20 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa) Fragment:UNP residues 458-765
Not recorded SO4 SULFATE ION × 2 5SF ~{N}'-(3,5-dimethoxyphenyl)-~{N}'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-~{N}-propan-2-yl-ethane-1,2-diamine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.75;277 K;18-20% PEG8000, 200mM Ammonium sulphate, 100mM PCTP, 20% (v/v) ethylene glycol
Resolution 1.63 Å R-free 0.206
5EW8 FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693 Deposited 2015-11-20 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa) Fragment:UNP residues 458-765
Not recorded SO4 SULFATE ION × 1 5SF ~{N}'-(3,5-dimethoxyphenyl)-~{N}'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-~{N}-propan-2-yl-ethane-1,2-diamine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.75;277 K;18-20% PEG8000, 200mM Ammonium sulphate, 100mM PCTP, 20% (v/v) ethylene glycol
Resolution 1.63 Å R-free 0.206
5FLF DISEASE LINKED MUTATION IN FGFR Deposited 2015-10-26 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa) Fragment:KINASE DOMAIN, UNP RESIDUES 458-765
Mutation:YES SO4 SULFATE ION × 1 ACT ACETATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5;20 PEG 400, 0.75 M AMMONIUM SULPHATE, 0.1 M MAGNESIUM CHLORIDE, 0.1 M HEPES PH 7.5
Resolution 2.58 Å R-free 0.255
5FLF DISEASE LINKED MUTATION IN FGFR Deposited 2015-10-26 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa) Fragment:KINASE DOMAIN, UNP RESIDUES 458-765
Mutation:YES SO4 SULFATE ION × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5;20 PEG 400, 0.75 M AMMONIUM SULPHATE, 0.1 M MAGNESIUM CHLORIDE, 0.1 M HEPES PH 7.5
Resolution 2.58 Å R-free 0.255
5FLF DISEASE LINKED MUTATION IN FGFR Deposited 2015-10-26 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 458–765(308 aa) Fragment:KINASE DOMAIN, UNP RESIDUES 458-765
Mutation:YES SO4 SULFATE ION × 1 CL CHLORIDE ION × 1 PGE TRIETHYLENE GLYCOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5;20 PEG 400, 0.75 M AMMONIUM SULPHATE, 0.1 M MAGNESIUM CHLORIDE, 0.1 M HEPES PH 7.5
Resolution 2.58 Å R-free 0.255
5FLF DISEASE LINKED MUTATION IN FGFR Deposited 2015-10-26 Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain D 458–765(308 aa) Fragment:KINASE DOMAIN, UNP RESIDUES 458-765
Mutation:YES SO4 SULFATE ION × 5 CL CHLORIDE ION × 3 PGE TRIETHYLENE GLYCOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5;20 PEG 400, 0.75 M AMMONIUM SULPHATE, 0.1 M MAGNESIUM CHLORIDE, 0.1 M HEPES PH 7.5
Resolution 2.58 Å R-free 0.255
5FLF DISEASE LINKED MUTATION IN FGFR Deposited 2015-10-26 Assembly 5 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain E 458–765(308 aa) Fragment:KINASE DOMAIN, UNP RESIDUES 458-765
Mutation:YES SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5;20 PEG 400, 0.75 M AMMONIUM SULPHATE, 0.1 M MAGNESIUM CHLORIDE, 0.1 M HEPES PH 7.5
Resolution 2.58 Å R-free 0.255
5O49 Human FGF in complex with a covalent inhibitor Deposited 2017-05-26 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa)
Not recorded 9K5 [(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methyl 3-fluorosulfonylbenzoate × 1 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;277 K;18-20% (w/v) PEG8000, 200mM ammonium sulphate, 100mM PCTP pH 6.75 and 20% (v/v) ethylene glycol
Resolution 1.91 Å R-free 0.220
5O49 Human FGF in complex with a covalent inhibitor Deposited 2017-05-26 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa)
Not recorded 9K5 [(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methyl 3-fluorosulfonylbenzoate × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;277 K;18-20% (w/v) PEG8000, 200mM ammonium sulphate, 100mM PCTP pH 6.75 and 20% (v/v) ethylene glycol
Resolution 1.91 Å R-free 0.220
5O4A Human FGF in complex with a covalent inhibitor Deposited 2017-05-26 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa) Fragment:UNP residues 458-765
Not recorded SO4 SULFATE ION × 2 GOL GLYCEROL × 1 9K8 [(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methyl 4-ethyl-3-fluorosulfonyl-benzoate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;18-20% (w/v) PEG8000, 200mM ammonium sulphate, 100mM PCTP pH 6.75 and 20% (v/v) ethylene glycol
Resolution 2.01 Å R-free 0.225
5O4A Human FGF in complex with a covalent inhibitor Deposited 2017-05-26 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa) Fragment:UNP residues 458-765
Not recorded SO4 SULFATE ION × 1 9K8 [(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methyl 4-ethyl-3-fluorosulfonyl-benzoate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;18-20% (w/v) PEG8000, 200mM ammonium sulphate, 100mM PCTP pH 6.75 and 20% (v/v) ethylene glycol
Resolution 2.01 Å R-free 0.225
5UQ0 FGFR1 kinase domain complex with fragment 2,2-dimethyl-2,3-dihydrobenzofuran-7-carboxamide Deposited 2017-02-05 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 457–763(307 aa) Fragment:UNP residues 457-763
Mutation:C488A, C584S WP1 2,2-dimethyl-2,3-dihydro-1-benzofuran-7-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;291 K;20% MPEG 5000, 0.1 M sodium cacodylate pH 7.5, 0.2 M ammonium sulfate
Resolution 2.30 Å R-free 0.294
5UQ0 FGFR1 kinase domain complex with fragment 2,2-dimethyl-2,3-dihydrobenzofuran-7-carboxamide Deposited 2017-02-05 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 457–763(307 aa) Fragment:UNP residues 457-763
Mutation:C488A, C584S WP1 2,2-dimethyl-2,3-dihydro-1-benzofuran-7-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;291 K;20% MPEG 5000, 0.1 M sodium cacodylate pH 7.5, 0.2 M ammonium sulfate
Resolution 2.30 Å R-free 0.294
5UR1 FGFR1 kinase domain complex with SN37333 in reversible binding mode Deposited 2017-02-09 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 457–763(307 aa)
Mutation:C488A, C584S YY9 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-{1-[4-(dimethylamino)but-2-enoyl]piperidin-4-yl}-7-(phenylamino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;291 K;20% MPEG 5000, 0.1 M sodium cacodylate pH 7.5, 0.2 M ammonium sulfate
Resolution 2.20 Å R-free 0.277
5UR1 FGFR1 kinase domain complex with SN37333 in reversible binding mode Deposited 2017-02-09 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 457–763(307 aa)
Mutation:C488A, C584S YY9 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-{1-[4-(dimethylamino)but-2-enoyl]piperidin-4-yl}-7-(phenylamino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;291 K;20% MPEG 5000, 0.1 M sodium cacodylate pH 7.5, 0.2 M ammonium sulfate
Resolution 2.20 Å R-free 0.277
5VND Crystal structure of FGFR1-Y563C (FGFR4 surrogate) covalently bound to H3B-6527 Deposited 2017-04-30 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 456–763(308 aa) Fragment:unp residues 458-765
Mutation:C486A, Y561C, C582S 9ES N-{2-[(6-{[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl](methyl)amino}pyrimidin-4-yl)amino]-5-(4-ethylpiperazin-1-yl)phenyl}propanamide × 1 SO4 SULFATE ION × 2 EDO 1,2-ETHANEDIOL × 9 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;298 K;20% PEG10000, 0.1M MES pH6.2, 0.3M Ammonium Sulphate, 5% Ethylene glycol
Resolution 2.20 Å R-free 0.223
5VND Crystal structure of FGFR1-Y563C (FGFR4 surrogate) covalently bound to H3B-6527 Deposited 2017-04-30 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 456–763(308 aa) Fragment:unp residues 458-765
Mutation:C486A, Y561C, C582S 9ES N-{2-[(6-{[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl](methyl)amino}pyrimidin-4-yl)amino]-5-(4-ethylpiperazin-1-yl)phenyl}propanamide × 1 SO4 SULFATE ION × 2 EDO 1,2-ETHANEDIOL × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;298 K;20% PEG10000, 0.1M MES pH6.2, 0.3M Ammonium Sulphate, 5% Ethylene glycol
Resolution 2.20 Å R-free 0.223
5VND Crystal structure of FGFR1-Y563C (FGFR4 surrogate) covalently bound to H3B-6527 Deposited 2017-04-30 Assembly 3 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 456–763(308 aa) Fragment:unp residues 458-765
Chain B 456–763(308 aa) Fragment:unp residues 458-765
Mutation:C486A, Y561C, C582S Mutation:C486A, Y561C, C582S 9ES N-{2-[(6-{[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl](methyl)amino}pyrimidin-4-yl)amino]-5-(4-ethylpiperazin-1-yl)phenyl}propanamide × 2 SO4 SULFATE ION × 4 EDO 1,2-ETHANEDIOL × 15 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;298 K;20% PEG10000, 0.1M MES pH6.2, 0.3M Ammonium Sulphate, 5% Ethylene glycol
Resolution 2.20 Å R-free 0.223
5W21 Crystal Structure of a 1:1:1 FGF23-FGFR1c-aKlotho Ternary Complex Deposited 2017-06-05 Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain C 142–365(224 aa) Fragment:D2 and D3 region (UNP residues 142-365)
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 7 ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;291 K;22% PEG350 MME, 0.1 M Tris-HCl, pH 8.0, 1 mM reduced glutathione, 1 mM oxidized glutathione
Resolution 3.00 Å R-free 0.278
5W59 Crystal structure of a monomeric human FGF9 in complex with the ectodomain of human FGFR1c Deposited 2017-06-14 Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain B 142–365(224 aa) Fragment:;Extracellular ligand binding domain of the "c" splice isoform (UNP residues 142-365) ;
Not recorded SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8;291 K;100 mM Tris, pH 8.0, 8% w/v PEG20000, 0.3 M sodium chloride, 40 mM L-proline
Resolution 2.50 Å R-free 0.221
5Z0S Crystal structure of FGFR1 kinase domain in complex with a novel inhibitor Deposited 2017-12-20 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa) Fragment:UNP residues 458-765
Mutation:C488A, C584S 960 1-[(6-chloroimidazo[1,2-b]pyridazin-3-yl)sulfonyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-b]pyridine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;277 K;0.1M Bis-Tris pH 6.5, 0.3M (NH4)2SO4, 15-20% PEG10000, 5% EG
Resolution 2.45 Å R-free 0.275
5Z0S Crystal structure of FGFR1 kinase domain in complex with a novel inhibitor Deposited 2017-12-20 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa) Fragment:UNP residues 458-765
Mutation:C488A, C584S 960 1-[(6-chloroimidazo[1,2-b]pyridazin-3-yl)sulfonyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-b]pyridine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;277 K;0.1M Bis-Tris pH 6.5, 0.3M (NH4)2SO4, 15-20% PEG10000, 5% EG
Resolution 2.45 Å R-free 0.275
5ZV2 FGFR-1 in complex with ligand lenvatinib Deposited 2018-05-09 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 461–764(304 aa) Fragment:KINASE DOMAIN
Mutation:C488A LEV 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;pH 7;277 K;17.70 % PEG-5000-MME, 0.20 M (NH4)2SO4, 0.10 M Tris pH 7.00, Cryo 25% Ethylenglycole in reservoir solution.
Resolution 2.86 Å R-free 0.269
5ZV2 FGFR-1 in complex with ligand lenvatinib Deposited 2018-05-09 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 461–764(304 aa) Fragment:KINASE DOMAIN
Mutation:C488A LEV 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;pH 7;277 K;17.70 % PEG-5000-MME, 0.20 M (NH4)2SO4, 0.10 M Tris pH 7.00, Cryo 25% Ethylenglycole in reservoir solution.
Resolution 2.86 Å R-free 0.269
6C18 FGFR1 kinase complex with inhibitor SN37115 Deposited 2018-01-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 457–763(307 aa) Fragment:UNP residues 457-763
Mutation:C486A, C582S YY5 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-{(3S)-1-[(2E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl}-7-[(propan-2-yl)amino]-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;291 K;20% MPEG 5000, 0.1 M sodium cacodylate pH 7.5, 0.2 M ammonium sulfate
Resolution 2.30 Å R-free 0.267
6C18 FGFR1 kinase complex with inhibitor SN37115 Deposited 2018-01-04 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 457–763(307 aa) Fragment:UNP residues 457-763
Mutation:C486A, C582S YY5 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-{(3S)-1-[(2E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl}-7-[(propan-2-yl)amino]-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;291 K;20% MPEG 5000, 0.1 M sodium cacodylate pH 7.5, 0.2 M ammonium sulfate
Resolution 2.30 Å R-free 0.267
6C19 FGFR1 kinase complex with inhibitor SN36985 Deposited 2018-01-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 457–763(307 aa)
Mutation:C488A, C584S YY7 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-{(3S)-1-[(2E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl}-7-(methylamino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;291 K;20% MPEG 5000, 0.1 M sodium cacodylate pH 7.5, 0.2 M ammonium sulfate
Resolution 2.12 Å R-free 0.239
6C19 FGFR1 kinase complex with inhibitor SN36985 Deposited 2018-01-04 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 457–763(307 aa)
Mutation:C488A, C584S YY7 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-{(3S)-1-[(2E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl}-7-(methylamino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;291 K;20% MPEG 5000, 0.1 M sodium cacodylate pH 7.5, 0.2 M ammonium sulfate
Resolution 2.12 Å R-free 0.239
6C1B FGFR1 kinase complex with inhibitor SN37118 Deposited 2018-01-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 457–763(307 aa) Fragment:UNP residues 457-763
Mutation:C486A, C582S YY4 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-{(3S)-1-[(2E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl}-7-(phenylamino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;291 K;20% MPEG 5000, 0.1 M sodium cacodylate pH 7.5, 0.2 M ammonium sulfate
Resolution 2.00 Å R-free 0.255
6C1B FGFR1 kinase complex with inhibitor SN37118 Deposited 2018-01-04 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 457–763(307 aa) Fragment:UNP residues 457-763
Mutation:C486A, C582S YY4 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-{(3S)-1-[(2E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl}-7-(phenylamino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;291 K;20% MPEG 5000, 0.1 M sodium cacodylate pH 7.5, 0.2 M ammonium sulfate
Resolution 2.00 Å R-free 0.255
6C1C FGFR1 kinase complex with inhibitor SN37116 Deposited 2018-01-04 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 457–763(307 aa) Fragment:UNP residues 457-763
Mutation:C486A, C582S YY6 7-(cyclohexylamino)-3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-{(3S)-1-[(2E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl}-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;291 K;20% MPEG 5000, 0.1 M sodium cacodylate pH 7.5, 0.2 M ammonium sulfate
Resolution 2.15 Å R-free 0.270
6C1C FGFR1 kinase complex with inhibitor SN37116 Deposited 2018-01-04 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 457–763(307 aa) Fragment:UNP residues 457-763
Mutation:C486A, C582S YY6 7-(cyclohexylamino)-3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-{(3S)-1-[(2E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl}-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;291 K;20% MPEG 5000, 0.1 M sodium cacodylate pH 7.5, 0.2 M ammonium sulfate
Resolution 2.15 Å R-free 0.270
6C1O FGFR1 kinase domain complexed with FIIN-1 Deposited 2018-01-05 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 457–763(307 aa)
Not recorded MK9 N-(3-{[3-(2,6-dichloro-3,5-dimethoxyphenyl)-7-{[4-(diethylamino)butyl]amino}-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl]methyl}phenyl)prop-2-enamide × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;291 K;20% MPEG 5000, 0.1 M sodium cacodylate pH 7.5, 0.2 M ammonium sulfate
Resolution 2.29 Å R-free 0.276
6C1O FGFR1 kinase domain complexed with FIIN-1 Deposited 2018-01-05 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 457–763(307 aa)
Not recorded MK9 N-(3-{[3-(2,6-dichloro-3,5-dimethoxyphenyl)-7-{[4-(diethylamino)butyl]amino}-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl]methyl}phenyl)prop-2-enamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;291 K;20% MPEG 5000, 0.1 M sodium cacodylate pH 7.5, 0.2 M ammonium sulfate
Resolution 2.29 Å R-free 0.276
6ITJ Crystal structure of FGFR1 kinase domain in complex with compound 3 Deposited 2018-11-23 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa) Fragment:UNP residues 458-765
Mutation:C488A, C584S AXU 4-azanyl-3-(3,5-dimethyl-1-benzofuran-2-yl)-2-phenyl-6~{H}-pyrazolo[3,4-d]pyridazin-7-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;277 K;0.1M Bis-Tris pH 6.5, 0.3M (NH4)2SO4, 15-20% PEG10000, 5% EG
Resolution 1.99 Å R-free 0.244
6ITJ Crystal structure of FGFR1 kinase domain in complex with compound 3 Deposited 2018-11-23 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa) Fragment:UNP residues 458-765
Mutation:C488A, C584S AXU 4-azanyl-3-(3,5-dimethyl-1-benzofuran-2-yl)-2-phenyl-6~{H}-pyrazolo[3,4-d]pyridazin-7-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;277 K;0.1M Bis-Tris pH 6.5, 0.3M (NH4)2SO4, 15-20% PEG10000, 5% EG
Resolution 1.99 Å R-free 0.244
6MZQ TAS-120 in reversible binding mode with FGFR1 Deposited 2018-11-05 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 368–674(307 aa)
Not recorded TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;291 K;MPEG 5000, sodium cacodylate, ammonium sulfate
Resolution 2.00 Å R-free 0.230
6MZQ TAS-120 in reversible binding mode with FGFR1 Deposited 2018-11-05 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 368–674(307 aa)
Not recorded TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;291 K;MPEG 5000, sodium cacodylate, ammonium sulfate
Resolution 2.00 Å R-free 0.230
6MZW TAS-120 covalent complex with FGFR1 Deposited 2018-11-05 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 368–674(307 aa)
Not recorded TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;291 K;MPEG 5000, ammonium sulfate, sodium cacodylate
Resolution 2.20 Å R-free 0.297
6MZW TAS-120 covalent complex with FGFR1 Deposited 2018-11-05 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 368–674(307 aa)
Not recorded TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;291 K;MPEG 5000, ammonium sulfate, sodium cacodylate
Resolution 2.20 Å R-free 0.297
6NVL FGFR1 complex with N-(2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-3-methylphenyl)acrylamide Deposited 2019-02-05 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa)
Mutation:C584S SO4 SULFATE ION × 1 XL6 N-[2-({5-[(2,6-dichloro-3,5-dimethoxyphenyl)methoxy]pyrimidin-2-yl}amino)-3-methylphenyl]propanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 7.5;291 K;90 mM NPS salt mixture (30 mM sodium nitrate, 30 mM sodium phosphate dibasic, 30 mM ammonium sulfatesulfate), 100 mM HEPES/MOPS pH 7.5, and 50% v/v of a precipitant mixture of 40% v/v PEG 500 MME and 20 % w/v PEG 20,000
Resolution 2.70 Å R-free 0.263
6NVL FGFR1 complex with N-(2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-3-methylphenyl)acrylamide Deposited 2019-02-05 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa)
Mutation:C584S SO4 SULFATE ION × 1 XL6 N-[2-({5-[(2,6-dichloro-3,5-dimethoxyphenyl)methoxy]pyrimidin-2-yl}amino)-3-methylphenyl]propanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 7.5;291 K;90 mM NPS salt mixture (30 mM sodium nitrate, 30 mM sodium phosphate dibasic, 30 mM ammonium sulfatesulfate), 100 mM HEPES/MOPS pH 7.5, and 50% v/v of a precipitant mixture of 40% v/v PEG 500 MME and 20 % w/v PEG 20,000
Resolution 2.70 Å R-free 0.263
6NVL FGFR1 complex with N-(2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-3-methylphenyl)acrylamide Deposited 2019-02-05 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 458–765(308 aa)
Mutation:C584S XL6 N-[2-({5-[(2,6-dichloro-3,5-dimethoxyphenyl)methoxy]pyrimidin-2-yl}amino)-3-methylphenyl]propanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 7.5;291 K;90 mM NPS salt mixture (30 mM sodium nitrate, 30 mM sodium phosphate dibasic, 30 mM ammonium sulfatesulfate), 100 mM HEPES/MOPS pH 7.5, and 50% v/v of a precipitant mixture of 40% v/v PEG 500 MME and 20 % w/v PEG 20,000
Resolution 2.70 Å R-free 0.263
6NVL FGFR1 complex with N-(2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-3-methylphenyl)acrylamide Deposited 2019-02-05 Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain D 458–765(308 aa)
Mutation:C584S SO4 SULFATE ION × 3 XL6 N-[2-({5-[(2,6-dichloro-3,5-dimethoxyphenyl)methoxy]pyrimidin-2-yl}amino)-3-methylphenyl]propanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 7.5;291 K;90 mM NPS salt mixture (30 mM sodium nitrate, 30 mM sodium phosphate dibasic, 30 mM ammonium sulfatesulfate), 100 mM HEPES/MOPS pH 7.5, and 50% v/v of a precipitant mixture of 40% v/v PEG 500 MME and 20 % w/v PEG 20,000
Resolution 2.70 Å R-free 0.263
6P68 Crystal structure of FGFR1-Y563C (FGFR4 surrogate) covalently bound to compound 22. Deposited 2019-06-03 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa)
Mutation:Y563C,C488A O1Y N-{3-[(6-{[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl](methyl)amino}pyrimidin-4-yl)amino]-1-(2-hydroxyethyl)-1H-pyrazol-4-yl}prop-2-enamide × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;1:1 mix of protein + reservoir Protein at ~15 mg/mL formulated in: 20mM Tris pH 8, 20mM NaCl, 2mM TCEP Reservoir: 14-18% PEG 10K 0.3 M (NH4)2SO4 0.1 M MES pH 6.5 5% ethylene glycol
Resolution 2.90 Å R-free 0.303
6P68 Crystal structure of FGFR1-Y563C (FGFR4 surrogate) covalently bound to compound 22. Deposited 2019-06-03 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa)
Mutation:Y563C,C488A O1Y N-{3-[(6-{[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl](methyl)amino}pyrimidin-4-yl)amino]-1-(2-hydroxyethyl)-1H-pyrazol-4-yl}prop-2-enamide × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;1:1 mix of protein + reservoir Protein at ~15 mg/mL formulated in: 20mM Tris pH 8, 20mM NaCl, 2mM TCEP Reservoir: 14-18% PEG 10K 0.3 M (NH4)2SO4 0.1 M MES pH 6.5 5% ethylene glycol
Resolution 2.90 Å R-free 0.303
6P68 Crystal structure of FGFR1-Y563C (FGFR4 surrogate) covalently bound to compound 22. Deposited 2019-06-03 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 458–765(308 aa)
Mutation:Y563C,C488A O1Y N-{3-[(6-{[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl](methyl)amino}pyrimidin-4-yl)amino]-1-(2-hydroxyethyl)-1H-pyrazol-4-yl}prop-2-enamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;1:1 mix of protein + reservoir Protein at ~15 mg/mL formulated in: 20mM Tris pH 8, 20mM NaCl, 2mM TCEP Reservoir: 14-18% PEG 10K 0.3 M (NH4)2SO4 0.1 M MES pH 6.5 5% ethylene glycol
Resolution 2.90 Å R-free 0.303
6P69 Crystal structure of FGFR1-Y563C (FGFR4 surrogate) covalently bound to compound 11. Deposited 2019-06-03 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa)
Mutation:C488A, Y563C SO4 SULFATE ION × 1 EDO 1,2-ETHANEDIOL × 2 O21 N-{2-[(6-{[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl][3-(4-methylpiperazin-1-yl)propyl]amino}pyrimidin-4-yl)amino]phenyl}prop-2-enamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;1:1 mix of protein + reservoir Protein at ~15 mg/mL formulated in: 20mM Tris pH 8, 20mM NaCl, 2mM TCEP Reservoir: 14-18% PEG 10K 0.3 M (NH4)2SO4 0.1 M MES pH 6.5 5% ethylene glycol
Resolution 2.20 Å R-free 0.245
6P69 Crystal structure of FGFR1-Y563C (FGFR4 surrogate) covalently bound to compound 11. Deposited 2019-06-03 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa)
Mutation:C488A, Y563C SO4 SULFATE ION × 2 EDO 1,2-ETHANEDIOL × 1 O21 N-{2-[(6-{[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl][3-(4-methylpiperazin-1-yl)propyl]amino}pyrimidin-4-yl)amino]phenyl}prop-2-enamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;1:1 mix of protein + reservoir Protein at ~15 mg/mL formulated in: 20mM Tris pH 8, 20mM NaCl, 2mM TCEP Reservoir: 14-18% PEG 10K 0.3 M (NH4)2SO4 0.1 M MES pH 6.5 5% ethylene glycol
Resolution 2.20 Å R-free 0.245
7OZB FGFR1 kinase domain (residues 458-765) with mutations C488A, C584S in complex with 38. Deposited 2021-06-27 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain AAA 458–765(308 aa) Fragment:UNP residues 458-765
Not recorded 47I 4-[3-(4-piperazin-4-ium-1-ylphenyl)-1H-indazol-6-yl]phenol × 1 SO4 SULFATE ION × 2 EDO 1,2-ETHANEDIOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.7;291 K;0.185M ammonium sulfate, 20% v/v ethylene glycol, 17% w/v PEG 8000, 0.1M PCPT
Resolution 1.71 Å R-free 0.244
7OZB FGFR1 kinase domain (residues 458-765) with mutations C488A, C584S in complex with 38. Deposited 2021-06-27 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain BBB 458–765(308 aa) Fragment:UNP residues 458-765
Not recorded 47I 4-[3-(4-piperazin-4-ium-1-ylphenyl)-1H-indazol-6-yl]phenol × 1 SO4 SULFATE ION × 3 EDO 1,2-ETHANEDIOL × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.7;291 K;0.185M ammonium sulfate, 20% v/v ethylene glycol, 17% w/v PEG 8000, 0.1M PCPT
Resolution 1.71 Å R-free 0.244
7OZD FGFR1 kinase domain (residues 458-765) with mutations C488A, C584S in complex with 34. Deposited 2021-06-27 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain AAA 458–765(308 aa) Fragment:UNP residues 458-765
Not recorded 42I N-[6-(4-hydroxyphenyl)-1H-indazol-3-yl]benzamide × 1 SO4 SULFATE ION × 5 EDO 1,2-ETHANEDIOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.7;291 K;0.185M ammonium sulfate, 20% v/v ethylene glycol, 17% w/v PEG 8000, 0.1M PCPT
Resolution 1.82 Å R-free 0.241
7OZD FGFR1 kinase domain (residues 458-765) with mutations C488A, C584S in complex with 34. Deposited 2021-06-27 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain BBB 458–765(308 aa) Fragment:UNP residues 458-765
Not recorded 42I N-[6-(4-hydroxyphenyl)-1H-indazol-3-yl]benzamide × 1 SO4 SULFATE ION × 3 EDO 1,2-ETHANEDIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.7;291 K;0.185M ammonium sulfate, 20% v/v ethylene glycol, 17% w/v PEG 8000, 0.1M PCPT
Resolution 1.82 Å R-free 0.241
7OZF FGFR1 kinase domain (residues 458-765) with mutations C488A, C584S in complex with 19. Deposited 2021-06-28 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain AAA 458–765(308 aa) Fragment:UNP residues 458-765
Not recorded 466 N-[6-(3-ethoxyphenyl)-1H-indazol-3-yl]benzamide × 1 SO4 SULFATE ION × 1 EDO 1,2-ETHANEDIOL × 2 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.7;291 K;0.185M ammonium sulfate, 20% v/v ethylene glycol, 17% w/v PEG 8000, 0.1M PCPT
Resolution 1.82 Å R-free 0.242
7OZF FGFR1 kinase domain (residues 458-765) with mutations C488A, C584S in complex with 19. Deposited 2021-06-28 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain BBB 458–765(308 aa) Fragment:UNP residues 458-765
Not recorded 466 N-[6-(3-ethoxyphenyl)-1H-indazol-3-yl]benzamide × 1 EDO 1,2-ETHANEDIOL × 2 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.7;291 K;0.185M ammonium sulfate, 20% v/v ethylene glycol, 17% w/v PEG 8000, 0.1M PCPT
Resolution 1.82 Å R-free 0.242
7TNH Crystal structure of CSF1R kinase domain in complex with DP-6233 Deposited 2022-01-21 Assembly 1 Insufficient information Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 577–597(21 aa)
Not recorded NA SODIUM ION × 1 CL CHLORIDE ION × 4 I9W 2,2-dimethyl-N-[(6-methyl-5-{[2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl]oxy}pyridin-2-yl)carbamoyl]propanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;295 K;CSF1R at 10.7 mg/mL in 50 mM Tris pH 7.5, 200 mM NaCl, 5% glycerol with 5-fold excess of arylamide compound against 10% PEG 10,000, 0.1 M MES pH 6.5 and 0.1 M magnesium acetate soaked over two nights with 1 mM DP-6233 and 20% ethylene glycol as cryo
Resolution 2.70 Å R-free 0.269
7WCL Crystal structure of FGFR1 kinase domain with Pemigatinib Deposited 2021-12-20 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa)
Mutation:C584S 8ZF 11-[2,6-bis(fluoranyl)-3,5-dimethoxy-phenyl]-13-ethyl-4-(morpholin-4-ylmethyl)-5,7,11,13-tetrazatricyclo[7.4.0.0^{2,6}]trideca-1(9),2(6),3,7-tetraen-12-one × 1 SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277.15 K;18% (w/v) PEG 8000, 0.2 M LiSO4, 0.1 M MES (pH 6.5)
Resolution 2.50 Å R-free 0.230
7WCL Crystal structure of FGFR1 kinase domain with Pemigatinib Deposited 2021-12-20 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa)
Mutation:C584S 8ZF 11-[2,6-bis(fluoranyl)-3,5-dimethoxy-phenyl]-13-ethyl-4-(morpholin-4-ylmethyl)-5,7,11,13-tetrazatricyclo[7.4.0.0^{2,6}]trideca-1(9),2(6),3,7-tetraen-12-one × 1 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277.15 K;18% (w/v) PEG 8000, 0.2 M LiSO4, 0.1 M MES (pH 6.5)
Resolution 2.50 Å R-free 0.230
8JMZ FGFR1 kinase domain with sulfatinib Deposited 2023-06-05 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa)
Mutation:C129S UKI Sulfatinib × 1 SO4 SULFATE ION × 6 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277.15 K;0.1 M MES pH 6.6,34% PEG 8000,0.2 M ammonium sulfate
Resolution 1.99 Å R-free 0.205
8JMZ FGFR1 kinase domain with sulfatinib Deposited 2023-06-05 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa)
Mutation:C129S UKI Sulfatinib × 1 SO4 SULFATE ION × 3 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277.15 K;0.1 M MES pH 6.6,34% PEG 8000,0.2 M ammonium sulfate
Resolution 1.99 Å R-free 0.205
8JQI Cryo EM map of full length PLC gamma 2 and FGFR1 Kinase Domain Deposited 2023-06-14 Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain B 1–822(822 aa)
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.9;25 mM Tris pH 7.9, 150 mM NaCl, 1mM TCEP
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.10 Å
8XLO FGFR1 kinase domain with a dual-warhead covalent inhibitor CXF-007 Deposited 2023-12-26 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa)
Mutation:C584S A1LVQ CXF007 × 1 SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277.15 K;18% (w/v) PEG 8000, 0.2 M Li2SO4, and 0.1 M MES, pH 6.5
Resolution 2.36 Å R-free 0.255
8XLO FGFR1 kinase domain with a dual-warhead covalent inhibitor CXF-007 Deposited 2023-12-26 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa)
Mutation:C584S A1LVQ CXF007 × 1 SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277.15 K;18% (w/v) PEG 8000, 0.2 M Li2SO4, and 0.1 M MES, pH 6.5
Resolution 2.36 Å R-free 0.255
8XZ7 FGFR1 kinase domain with a covalent inhibitor 10h Deposited 2024-01-20 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa)
Mutation:C129S SO4 SULFATE ION × 3 A1LWW 5-azanyl-3-[2-[4,6-bis(fluoranyl)-2-methyl-3~{H}-benzimidazol-5-yl]ethynyl]-1-[[3-(prop-2-enoylamino)phenyl]methyl]pyrazole-4-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;18% PEG 8000, 0.2 M Li2SO4, and 0.1 M MES, pH 6.5
Resolution 1.75 Å R-free 0.225
8XZ7 FGFR1 kinase domain with a covalent inhibitor 10h Deposited 2024-01-20 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa)
Mutation:C129S SO4 SULFATE ION × 2 A1LWW 5-azanyl-3-[2-[4,6-bis(fluoranyl)-2-methyl-3~{H}-benzimidazol-5-yl]ethynyl]-1-[[3-(prop-2-enoylamino)phenyl]methyl]pyrazole-4-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;18% PEG 8000, 0.2 M Li2SO4, and 0.1 M MES, pH 6.5
Resolution 1.75 Å R-free 0.225
8Y22 FGFR1 kinase domain with a covalent inhibitor 9g Deposited 2024-01-25 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa)
Mutation:C127S A1LW9 ~{N}-[4-[[4-azanyl-3-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]phenyl]propanamide × 1 SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;18% PEG 8000, 0.2 M Li2SO4, and 0.1 M MES, pH 6.5
Resolution 2.79 Å R-free 0.260
8Y22 FGFR1 kinase domain with a covalent inhibitor 9g Deposited 2024-01-25 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa)
Mutation:C127S A1LW9 ~{N}-[4-[[4-azanyl-3-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]phenyl]propanamide × 1 SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;18% PEG 8000, 0.2 M Li2SO4, and 0.1 M MES, pH 6.5
Resolution 2.79 Å R-free 0.260
8YKI FGFR-1 in complex with ligand tasurgratinib Deposited 2024-03-05 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 461–774(314 aa)
Mutation:C488A A1LY1 Tasurgratinib × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;18% w/v PEG 3350, 0.2M (NH4)2 TARTRATE
Resolution 2.79 Å R-free 0.288
8YKI FGFR-1 in complex with ligand tasurgratinib Deposited 2024-03-05 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 461–774(314 aa)
Mutation:C488A A1LY1 Tasurgratinib × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;18% w/v PEG 3350, 0.2M (NH4)2 TARTRATE
Resolution 2.79 Å R-free 0.288
9CD5 FGFR1 Kinase Domain Soak with Inhibitor TYRA-300 Deposited 2024-06-24 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa)
Mutation:C488A, C584S EDO 1,2-ETHANEDIOL × 2 A1AV2 (3P)-5-[(1R)-1-(3,5-dichloropyridin-4-yl)ethoxy]-3-{6-[6-(methanesulfonyl)-2,6-diazaspiro[3.3]heptan-2-yl]pyridin-3-yl}-1H-indazole × 1 SO4 SULFATE ION × 9 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;277 K;25%P8K, 25% EG, 0.25M AS, 0.1MPCTP pH7.5
Resolution 2.94 Å R-free 0.263
9CD5 FGFR1 Kinase Domain Soak with Inhibitor TYRA-300 Deposited 2024-06-24 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa)
Mutation:C488A, C584S EDO 1,2-ETHANEDIOL × 1 A1AV2 (3P)-5-[(1R)-1-(3,5-dichloropyridin-4-yl)ethoxy]-3-{6-[6-(methanesulfonyl)-2,6-diazaspiro[3.3]heptan-2-yl]pyridin-3-yl}-1H-indazole × 1 SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7.5;277 K;25%P8K, 25% EG, 0.25M AS, 0.1MPCTP pH7.5
Resolution 2.94 Å R-free 0.263
9U7G FGFR1 kinase domain with a macrocyclic compound 8g Deposited 2025-03-24 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa)
Not recorded A1EOH (E)-4-methyl-17-(1-methyl-1H-pyrazol-4-yl)-7,10-dioxa-4-aza-1(3,6)-imidazo[1,2-b]pyridazina-2(3,5)-pyridinacyclodecaphan-3-one × 1 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277.15 K;20% (w/v) PEG 8000, 0.2 M LiSO4, and 0.1 M MES, pH 6.5
Resolution 1.66 Å R-free 0.216
9U7G FGFR1 kinase domain with a macrocyclic compound 8g Deposited 2025-03-24 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa)
Not recorded A1EOH (E)-4-methyl-17-(1-methyl-1H-pyrazol-4-yl)-7,10-dioxa-4-aza-1(3,6)-imidazo[1,2-b]pyridazina-2(3,5)-pyridinacyclodecaphan-3-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277.15 K;20% (w/v) PEG 8000, 0.2 M LiSO4, and 0.1 M MES, pH 6.5
Resolution 1.66 Å R-free 0.216
9UHC FGFR1 kinase domain with a covalent inhibitor 9p Deposited 2025-04-14 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa)
Not recorded A1EPE ~{N}-[1-methyl-3-[2-[1-(2-morpholin-4-ylethyl)pyrazol-4-yl]-5~{H}-pyrrolo[2,3-b]pyrazin-7-yl]indol-6-yl]propanamide × 1 SO4 SULFATE ION × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;18% (w/v) PEG 8000, 0.2 M LiSO4, and 0.1 M MES, pH 6.5
Resolution 1.88 Å R-free 0.205
9UHC FGFR1 kinase domain with a covalent inhibitor 9p Deposited 2025-04-14 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa)
Not recorded A1EPE ~{N}-[1-methyl-3-[2-[1-(2-morpholin-4-ylethyl)pyrazol-4-yl]-5~{H}-pyrrolo[2,3-b]pyrazin-7-yl]indol-6-yl]propanamide × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;18% (w/v) PEG 8000, 0.2 M LiSO4, and 0.1 M MES, pH 6.5
Resolution 1.88 Å R-free 0.205
9UHI FGFR1 kinase domain with a covalent inhibitor 9o Deposited 2025-04-14 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa)
Not recorded A1EPF ~{N}-[1-methyl-3-[3-[1-(2-morpholin-4-ylethyl)pyrazol-4-yl]quinoxalin-5-yl]indol-6-yl]propanamide × 1 SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;16% (w/v) PEG 8000, 0.2 M LiSO4, and 0.1 M MES, pH 6.5
Resolution 1.76 Å R-free 0.197
9UHI FGFR1 kinase domain with a covalent inhibitor 9o Deposited 2025-04-14 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa)
Not recorded A1EPF ~{N}-[1-methyl-3-[3-[1-(2-morpholin-4-ylethyl)pyrazol-4-yl]quinoxalin-5-yl]indol-6-yl]propanamide × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277 K;16% (w/v) PEG 8000, 0.2 M LiSO4, and 0.1 M MES, pH 6.5
Resolution 1.76 Å R-free 0.197
9VLJ Crystal structure of FGFR1 in complex with covalent inhibitor 10a Deposited 2025-06-25 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 458–765(308 aa)
Not recorded A1ESP ~{N}-[3-[2-[[3-[2-(dimethylamino)ethylsulfamoylmethyl]phenyl]amino]pyrimidin-4-yl]-1-methyl-indol-6-yl]propanamide × 1 SO4 SULFATE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277.15 K;18% (w/v) PEG 8000, 0.2 M Li2SO4, and 0.1 M MES, pH 6.5
Resolution 1.81 Å R-free 0.215
9VLJ Crystal structure of FGFR1 in complex with covalent inhibitor 10a Deposited 2025-06-25 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 458–765(308 aa)
Not recorded A1ESP ~{N}-[3-[2-[[3-[2-(dimethylamino)ethylsulfamoylmethyl]phenyl]amino]pyrimidin-4-yl]-1-methyl-indol-6-yl]propanamide × 1 SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;277.15 K;18% (w/v) PEG 8000, 0.2 M Li2SO4, and 0.1 M MES, pH 6.5
Resolution 1.81 Å R-free 0.215